fidaxomicin

fidaxomicin
IUPAC name	(3R,4S,5S,6R,7R,10S,11R,12S,13S,14R,15R,17S,18S,19S,20S,21S,24S,25S,26R)-26-{[(2S,5S,6S)-5-amino-2-{[(2S,3S,6S)-3-amino-6-methyloxan-2-yl]oxy}-6-methyloxan-4-yl]oxy}-3,4,5,6,7,19,20,21,24,25,26-undecahydro-7,18,20,21,24-pentahydroxy-3,15-dimethoxy-4,10,12,14,16,22-hexamethyl-9,23-dioxo-8,30-dioxa-29-azatetracyclo[23.3.1.15,8.114,17]triaconta-1(28),2,4,10,12,14(30),15,17,25(29)-nonaen-11-yl 3-methylbutanoate
Width	200
CAS number	873857-62-6
DrugBank	DB08860
ATC prefix	A07
ATC suffix	AA12

fidaxomicin is a narrow-spectrum macrocyclic antibiotic drug utilized for the treatment of Clostridioides difficile infection. It is marketed under the brand name Dificid by Merck & Co. and functions by inhibiting bacterial RNA polymerase. This agent demonstrates high specificity for Clostridioides difficile while largely sparing the normal gut microbiota, which is a critical factor in preventing recurrence.

Medical uses

Fidaxomicin is indicated specifically for the treatment of Clostridioides difficile-associated diarrhea in adults. Clinical trials, such as those published in The New England Journal of Medicine, have demonstrated its non-inferiority to vancomycin for initial clinical cure, with a superior sustained clinical response, largely attributed to lower recurrence rates. Its use is generally reserved for initial episodes or first recurrences, particularly when minimizing recurrence is a priority, as recommended by guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. It is not effective against systemic infections due to its minimal systemic absorption.

Adverse effects

The adverse effect profile of fidaxomicin is generally mild. The most common adverse reactions reported in clinical studies involve the gastrointestinal tract, including nausea, vomiting, and abdominal pain. Hypersensitivity reactions, including angioedema and dyspnea, have been reported rarely. Due to its minimal absorption, systemic adverse effects are uncommon, making it a well-tolerated option compared to other agents like metronidazole, which carries risks of neuropathy and disulfiram-like reaction.

Pharmacology

Fidaxomicin exerts its bactericidal effect by selectively inhibiting the RNA polymerase enzyme of Clostridioides difficile. This inhibition occurs at the early stage of transcription, preventing the synthesis of essential proteins and leading to bacterial cell death. It exhibits a narrow spectrum of activity, showing potent efficacy against Clostridioides difficile while having little effect on prominent components of the anaerobic gut flora such as Bacteroides fragilis and other Firmicutes. Its pharmacokinetics are characterized by minimal systemic absorption; when administered orally, it acts locally within the gastrointestinal tract, with fecal concentrations exceeding the minimum inhibitory concentration for the pathogen by several orders of magnitude.

Chemistry

Fidaxomicin is a macrocyclic antibiotic belonging to the tiacumicin class. It is a natural product derived from the fermentation of the actinomycete Dactylosporangium aurantiacum. The complex molecular structure consists of an 18-membered macrocyclic lactone ring fused to a bicyclic sugar moiety, rhamnose, and an amino sugar, noviose. This structure is critical for its binding to the RNA polymerase target. It is formulated as a film-coated tablet for oral administration and is known chemically as a lipoglycopeptide.

History

Fidaxomicin was discovered by researchers at Optimer Pharmaceuticals, who identified its potent activity against Clostridioides difficile during screening programs for novel antibiotics. It received Food and Drug Administration approval in the United States in 2011, following phase III clinical trials that demonstrated its efficacy. Subsequent approval was granted by the European Medicines Agency in 2012. The development and approval of fidaxomicin represented a significant advance in the therapeutic arsenal against Clostridioides difficile infection, a major cause of hospital-acquired infection associated with significant morbidity and mortality.

Society and culture

Fidaxomicin is a significant entity in the ongoing battle against antimicrobial resistance and hospital-acquired infection. Its high cost, compared to older therapies like vancomycin, has been a point of discussion in health economics and formulary management within institutions like the National Health Service. The drug has been the subject of post-marketing studies and reviews by bodies such as the National Institute for Health and Care Excellence. Its brand name, Dificid, is widely recognized in infectious disease circles, and its development story is often cited in discussions about the challenges of antibiotic development within the pharmaceutical industry.

Category:Antibiotics Category:Macrolides Category:World Health Organization essential medicines